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Leukotrienes are a group of compounds belonging to the eicosanoid family that are 
formed from the metabolism of arachidonic acid by means of 5-lipoxigenase. 
Leukotriene C4 (LTC4) has a pronounced proinflammatory character and is formed by 
combining leukotriene A4 with glutation. This step is catalyzed mainly by the 
isoenzyme 4-4 of the hepatic glutation transferases,1 although other enzymes may 
participate in its formation.2,3 The liver plays a decisive part in the formation of this 
compound despite the fact that it can be synthesized along other cellular lines. In 
orthotopic liver transplant (OLT), the evaluation of the early functioning of the graft is, 
in many cases, complex. The difficulty of evaluation lies in the absence of specific 
markers to indicate (1) when the transplanted organ will prove viable notwithstanding 
the damage resulting from preservation, and (2) when these lesions are irreversible. 
The aim of this study is to determine whether there is a relationship between the 
ability to synthesize LTC4 immediately after OLT and the early functioning of the graft. 
 
 
 
MATERIALS AND METHODS 
 
Fifteen orthotopic liver allotransplants were performed on cross-bred dogs weighing 
between 20 and 30 kg. The technique de-scribed by Starzl et al4-6 was applied, with a 
few modifications. Euro-Collins solution was used for preservation, with a mean cold 
ischemia time of 93 ± 22 minutes. The animals were divided into two groups: In group I 
(n = 5) the preservation solution was used at 4°C, and in group II (n = 10) a 
preservation defect was caused by using the Euro-Collins solution at between 10° and 
15°C. 
 
During the anhepatic phase, a femoro-porto-jugular bypass was performed with 
spontaneous flow. Afterward, the venous anastomoses were performed in the 
following order: suprahepatic cava, infrahepatic cava, and porta. After revascularizing 
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the portal vein system, end-to-end arterial anastomosis was performed between the 
celiac axis of the donor and recipient. In some animals, this anastomosis is performed 
end-to-side between the hepatic artery of the donor and the exit of the celiac axis of 
the recipient. Reconstruction of the gallbladder was performed by means of 
cholecystoduodenostomy. In all cases, the animals were given an autotransfusion of 
blood extracted a week before the operation. None of the animals was given 
immunosuppressives. 
 
Blood tests were taken at the following points during the study: 1 week before the 
operation, after the endotracheal intubation before commencing the laparotomy, 15 
minutes after beginning the anhepatic stage, and then 5 minutes, 15 minutes, 1 hour, 
3 hours, 8 hours, and 24 hours after the graft had been revascularized through the 
portal veins. 
 
At all these points, tests measured glutamic-oxalacetic transaminase (GOT), glutamic-
pyruvic transaminase (GPT), prothrombin time, fibrinogen, lactic acid, and LTC4. 
  
Tests for LTC4 were performed by radioimmunoassay. Anti-body anti-LTC4 was a gift 
from Merck Frosst (Montreal, Canada). 
 
 
 
RESULTS 
 
The average survival for group I was 6.6 days (range 4 to 8), whereas all the animals of 
group II died in the first 24 hours with generalized hemoperitoneum; microscopic 
studies confirmed severe ischemic lesion of the liver in every case in this group. 
 
Figure 1 shows the levels of LTC4 in both groups. In group I, LTC4 was detected in all 
the animals immediately after revascularization, and the curve shows that levels were 
rising during the immediate postoperative period. In group II, no LTC4 was found in 
any of the animals after the anhepatic phase. The parameters calculated for graft 
viability are shown in Table 1. 
 
 
 
DISCUSSION 
 
Evaluation of early graft function in liver transplantation is often hindered by the 
absence of a specific marker to determine the degree of viability. The parameters that 
are generally used to assess graft functionality (GOT, GPT, bilirubin, alcaline 
phosphatase, prothrombin time, fibrinogen, and lactic acid) are not sensitive enough 
to measure the extent to which preservation damage can be reversed. Various clinical 
and experimental studies have recently brought the energy status of the preserved 
liver into relation with the graft's viability. 7,8 Other studies relate the early functioning 
of the graft with its ability to clear various substances, such as bile acids, endotoxins, 
amino acids, and hyaluronic acid.9-12 
In our study, the absence of LTC4 from peripheral blood after revascularization is 
related in all cases to reduced graft viability, which is probably due to the liver' s 
inability to perform glutation and/or enzyme synthesis. By contrast, LTC4 was detected 
in all the viable grafts immediately after revascularization. The capacity for 
synthesizing LTC4 may prove a good marker for early liver graft function. 
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Figure 1. Levels of LTC4 
 
 
 
 
 
 
 
 
 
 
Table 1. Parameters Calculated for Graft Viability 
 Time Postrevascularization 
 3 h 24 h 
 Group I Group II Group I Group II 
GOT 1408 ± 622 2648 ± 1211 1264 ± 483 7211 ± 1695 
GPT 1280 ± 579 2640 ± 1541 1311 ± 517 8037 ± 1831 
Lactic acid 7.1 ± 1.8 8.9 ± 2.1 4.6 ± 2.3 18.2 ± 3.1 
Fibrinogen 103 ± 48 39 ± 12 219 ± 54 41 ± 13 
 
 
 
 
 
 
